Compound library / Bone Health
Recombinant human PTH(1-34) fragment, FDA-approved for osteoporosis; the most-studied anabolic bone agent. Stimulates osteoblast activity to build new bone. Explored by some for faster fracture healing.
| Category | Bone Health |
|---|---|
| Typical route | Subcutaneous |
| Half-life | ~1 hour |
| Common dose range | 20 mcg once daily (approved dose) |
| Typical cycle length | Up to 24 months per FDA label |
BioHack Track models Teriparatide (Forteo) at a half-life of 1 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Supplied as a pre-filled pen; no reconstitution needed.
Refrigerate; do not freeze. Pen stable in use for 28 days.
Prescription medication with a boxed warning for osteosarcoma risk (based on rat data). Should not be used in patients with prior radiation to the skeleton or skeletal malignancy. Always follow with an antiresorptive agent.
Track Teriparatide (Forteo) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Teriparatide (Forteo) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.